NPR News: 05-21-2026 1PM EDT

Summary

---

NPR News Now: May 21, 2026, 1PM EDT

Host: Kristen Wright
Duration: ~5 minutes

---

Episode Overview

This episode of NPR News Now delivers the top headlines and updates on U.S.-Cuba relations following a criminal indictment of Raul Castro, breakthroughs in obesity drug research, Harvard's approach to grade inflation, and NOAA’s Atlantic hurricane forecast.

---

Key Discussion Points and Insights

1. U.S. Escalates Pressure on Cuba

[00:01 - 01:49]

• Indictment of Raul Castro:

  • The U.S. escalates its campaign against the Cuban government with a criminal indictment against former Cuban President Raul Castro.
  • Secretary of State Marco Rubio labels Cuba a national security threat and signals little hope for a negotiated settlement between the U.S. and Havana.
  • Rubio refuses to discuss how the U.S. might secure Castro’s extradition:
    • Marco Rubio (Secretary of State) [00:32]:
      “If we were trying to get him here, why would I say to the media what our plans are about that?... The bottom line, there's a lot. He's at that point he becomes a fugitive of American justice. And you know, if there's an announcement, we'll tell you. We'll tell you afterwards. Not before.”
  • Context: Rubio was en route to a NATO meeting in Sweden.
  • Raul Castro is charged with murder related to the 1996 shootdown of two “Brothers to the Rescue” aircraft, which killed four Cuban Americans.

• Broader U.S. Policy Moves:

  • Increased pressure follows the capture and extradition of Venezuela's President Nicolas Maduro to face charges in the U.S.
  • The administration has enforced a blockade on Cuba, leading to economic crisis on the island.
  • CIA recently engaged in talks in Cuba, preceding the indictment.

---

2. Eli Lilly's New Obesity Drug Shows Breakthrough Results

[02:11 - 02:56]

• About Retatrutide:

  • Eli Lilly’s experimental drug, Retatrutide, works on three hormones (GLP-1, GIP, glucagon), expanding on the mechanisms of current drugs like Wegovy and Zepbound.
  • Clinical Findings:
    • Over 80 weeks, participants on the highest dose lost more than 70 pounds on average, compared to only 5.5 pounds for those on placebo.
    • Outperformed other leading obesity drugs in similar studies.
    • Typical side effects: nausea and GI issues similar to other GLP-1 drugs.
  • The drug has not been submitted yet for FDA approval.

• Notable Quote:

  • Sydney Lupkin (NPR Health Correspondent) [02:11]:
    “People taking Eli Lilly's experimental drug lost more weight than people taking Zepbound or WeGovy over a similar time period.”

---

3. Harvard Moves to Curb Grade Inflation

[02:56 - 04:04]

• Policy Details:

  • Faculty have passed a proposal capping A grades to the top 20% of students per course, plus four additional As per class.
  • Aim: Restore meaning to grades, addressing the rise in As given (now >50% of undergrad grades, up from 25% two decades ago).

• Support and Criticism:

  • Support: Prof. Stephen Levitsky (Government, Harvard):
    • Quote [03:14]:
      “Students who work their tails off and really do outstanding work get the same grade as students who are smart and know how to BS their way through an essay and do good but not great work.”
  • Criticism: Some argue the cap unfairly assumes only a certain number of students can reach outstanding performance.
  • Policy will take effect Fall 2027.

---

4. NOAA Forecasts Below-Normal Atlantic Hurricane Season

[04:04 - 04:39]

• NOAA’s Prediction:
  • Forecast for 8 to 14 named storms, of which up to 3 could be major hurricanes.
  • Numbers are slightly below typical seasons, largely due to the El Niño weather pattern making hurricane formation less likely.
  • Host sign-off:
    • Kristen Wright [04:39]:
      “That's the weather pattern that makes it harder for hurricanes to form in the Atlantic Ocean.”

---

Notable Quotes

• Marco Rubio (Secretary of State) [00:32]:
  “If we were trying to get him here, why would I say to the media what our plans are about that?... The bottom line, there's a lot. He's at that point he becomes a fugitive of American justice. And you know, if there's an announcement, we'll tell you. We'll tell you afterwards. Not before.”

• Stephen Levitsky (Harvard Government Professor) [03:14]:
  “Students who work their tails off and really do outstanding work get the same grade as students who are smart and know how to BS their way through an essay and do good but not great work.”

• Sydney Lupkin (NPR Correspondent) [02:11]:
  “People taking Eli Lilly's experimental drug lost more weight than people taking Zepbound or WeGovy over a similar time period.”

---

Timestamps for Key Segments

• Raul Castro indictment/U.S.-Cuba relations: 00:01–01:49
• Eli Lilly obesity drug news: 02:11–02:56
• Harvard grade cap discussion: 02:56–04:04
• NOAA hurricane season forecast: 04:04–04:39

---

This episode delivers concise but impactful summaries of fast-evolving national and global news stories, characteristic of NPR’s straight news format.

Transcript

[A]

Live from NPR News in Washington, I'm Kristen Wright. Washington is stepping up its pressure campaign against the Cuban government. Former President Raul Castro's criminal indictment in the US Is an escalation of President Trump's push for regime change. Secretary of State Marco Rubio said today Cuba poses a national security threat and a negotiated peaceful agreement between the US And Havana isn't likely right now. He wouldn't reveal to reporters how the US Government plans to bring Fidel Castro's brother Raul.

[B]

I'm not going to talk about how we're going to get him here. If we were trying to get him here, why would I say to the media what our plans are about that? I know you have to ask, but why would I answer that? The bottom line, there's a lot. He's at that point he becomes a fugitive of American justice. And you know, if there's an announcement, we'll tell you. We'll tell you afterwards.

[A]

Not before Rubio was speaking in Florida on his way to a NATO foreign ministers meeting in Sweden. Raul Castro is charged with murder in connection to the 1996 downing of two civilian aircraft operated by the Miami based exile Brothers to the rescue. Four Cuban Americans were killed. NPR's Ryan Lucas reports.

[C]

The administration has been ramping up pressure on Cuba since early January after the successful US Military operation to capture Venezuela's President Nicolas Maduro and bring him to the US to face narco terrorism charges. Since then, the administration has ordered a blockade of Cuba that's cut off fuel shipments. Cuba's economy is in freefall. The CIA director just visited the island for talks. And now we have this Castro indictment. Castro is 94 years old. He's not in U.S. custody. But of course, the shadow of that Maduro raid hangs over all of this. Blanche was asked yesterday how far the US Would go to get its hands on Castro. He said there's a warrant out for his arrest. He expects Castro will show up on his own. Or as Blanche put it by another way.

[A]

NPR's Ryan Lucas reporting on Capitol Hill. The House of Representatives is expected to vote later today on a resolution to end the war with Iran. The pharmaceutical company Eli Lilly is studying a next generation obesity drug. It's not on the market yet, but new study results show it helped people lose more weight than the obesity injections and drugs already on the market. NPR's Sydney Lupkin reports.

[D]

Eli Lilly is researching Retatrutide. Unlike Wegovy and Zepbound, which target the GLP1 hormone, this new drug works on three hormones. GLP1 GIP and glucagon. The company says that in the clinical trial, people taking it for 80 weeks lost an average of more than seven 70 pounds at the highest dose. That's compared with five and a half pounds for the patients taking a placebo over the same time period. And people taking Eli Lilly's experimental drug lost more weight than people taking Zepbound or WeGovy over a similar time period. In other studies, common side effects were similar to other GLP1 drugs, including nausea and other gastrointestinal issues. Eli Lilly has not yet submitted retatrutide for Food and Drug Administration approval. Sidney Lupkin, NPR News.

[A]

This is NPR News from Washington. Faculty members at Harvard have overwhelmingly passed a new cap on the number of AS they can give out to students. Kirk Carapeza from member station GBH reports. The goal is to restore some meaning to letter grades at Harvard.

[E]

More than half of all grades awarded to undergraduates last year were as up from just a quarter two decades ago. Now the number of A grades in any given course will be limited to the top 20% of students, plus four additional A's per class. Government professor Stephen Levitsky supports that change. He says the status quo rewarded different levels of work with the same grade. Students who work their tails off and really do outstanding work get the same grade as students who are smart and know how to BS their way through an essay and do good but not great work. Critics argue the cap assumes only a limited number of students can produce outstanding work. The new policy takes effect in fall 2027. For NPR News, I'm Kirk Carapezza in Boston.

[A]

NOAA is forecasting a below normal Atlantic hurricane season. The national oceanic and Atmospheric Administration came out with its new outlook today. Forecasters are expecting eight to 14 named storms. That's a slightly smaller number than says as many as three of those could wind up being major hurricanes. The main reason is El Nino. That's the weather pattern that makes it harder for hurricanes to form in the Atlantic Ocean. I'm Kristen Wright, NPR News, in Washington.

[E]

Support for NPR Want to hear this podcast without sponsor breaks? Amazon prime members can listen to NPR News now Sponsor free through Amazon Music. Or you can also support NPR's vital journalism and get [e-mail] that's plus.npr.org.